Mitsuo Terada
Overview
Explore the profile of Mitsuo Terada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwatani T, Sasaki K, Machida R, Shien T, Hara F, Fujisawa T, et al.
Jpn J Clin Oncol
. 2024 Aug;
54(10):1093-1099.
PMID: 39178176
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and...
2.
Kusudo M, Terada M, Kureyama N, Wanifuchi-Endo Y, Fujita T, Asano T, et al.
Sci Rep
. 2024 Mar;
14(1):6485.
PMID: 38499598
Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X)...
3.
Iesato A, Fushimi A, Tahara R, Terada M, Iwase M, Kawamura C, et al.
Breast Cancer
. 2023 Nov;
31(1):63-74.
PMID: 37995024
Background: The internet, especially YouTube, has become a prominent source of health information. However, the quality and accuracy of medical content on YouTube vary, posing concerns about misinformation. This study...
4.
Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, et al.
Breast Cancer
. 2023 Oct;
30(6):872-884.
PMID: 37804479
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines...
5.
Kureyama N, Terada M, Kusudo M, Nozawa K, Wanifuchi-Endo Y, Fujita T, et al.
JMIR Form Res
. 2023 Sep;
7:e49452.
PMID: 37672310
Background: The widespread use of social media has made it easier for patients to access cancer information. However, a large amount of misinformation and harmful information that could negatively impact...
6.
Kato A, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, et al.
J Cancer Res Clin Oncol
. 2022 Oct;
149(8):4771-4782.
PMID: 36229542
Purpose: Tubulointerstitial nephritis antigen-like 1 (TINAGL1) was reported to suppress tumor metastasis and growth in triple-negative (TN) breast cancer. We aimed to determine the associations of TINAGL1 expression with clinicopathological...
7.
Hisada T, Kondo N, Wanifuchi-Endo Y, Osaga S, Fujita T, Asano T, et al.
Sci Rep
. 2022 Oct;
12(1):16515.
PMID: 36192404
Lethal giant larvae homolog 2 (LLGL2) and solute carrier family 7 member 5 (SLC7A5) have been reported to be involved in resistance to endocrine therapy. This study aimed to assess...
8.
Matsumoto N, Kondo N, Wanifuchi-Endo Y, Asano T, Hisada T, Uemoto Y, et al.
Surg Case Rep
. 2022 Aug;
8(1):157.
PMID: 35980544
Background: Granulocyte colony-stimulating factor (G-CSF) is increasingly used to prevent chemotherapy-associated febrile neutropenia. Generally, aortitis is not considered a side effect of G-CSF and is thought to be extremely rare....
9.
Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, et al.
Breast Cancer Res Treat
. 2022 Aug;
195(3):311-323.
PMID: 35941421
Purpose: Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the...
10.
Uemoto Y, Katsuta E, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, et al.
Am J Cancer Res
. 2022 May;
12(4):1593-1605.
PMID: 35530276
HECT domain E3 ubiquitin ligase 1 (HECTD1) has been reported to be a negative regulator of epithelial-mesenchymal transition and to decrease breast cancer invasion and metastasis. However, the clinical significance...